Health Maintenance in Inflammatory Bowel Disease

  • Fazia A. Mir
  • Sunanda V. Kane
Inflammatory Bowel Diseases (S Hanauer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease


Purpose of Review

Patients with inflammatory bowel disease (IBD) are not receiving preventative care services at the same rate as the general population. IBD patients are at increased risk for infections, osteoporosis, and certain malignancies secondary to their disease and as they are on immunosuppressive therapy. They are a younger population and often times consider their gastroenterologist as their primary care physician. In this review, we discuss up-to-date evidence pertaining to vaccine-preventable illnesses in the immunosuppressed IBD patient, screening for bone health, cervical cancer, skin malignancies, psychological wellbeing, and smoking cessation.

Recent Findings

Vaccinations are recommended in the IBD population as they are immunosuppressed and at increased risk for acquiring influenza and pneumonia. Not only are they at greater risk to acquire it but they also have a much severe complicated course. Ideally, IBD patients should be vaccinated prior to initiating immunosuppression and most inactive vaccines can be administered to them while they are on therapy. All IBD patients should be encouraged to stop smoking and have adequate vitamin D intake along with appropriate applicable cancer screenings.


Gastroenterologists must work in collaboration with primary care providers along with other specialists to help provide our patients well-rounded care for their IBD.


Health maintenance in inflammatory bowel disease Preventative care Vaccinations Bone health Skin cancer 


Compliance with Ethical Guidelines

Conflict of Interest

Sunanda Kane reports working as a consultant to AbbVie, Janssen, and Seres and received research funding from UCB. Fazia Mir declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152(2):313–321 e2.Google Scholar
  2. 2.
    • Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008; 14(2):253–8. The first article published before the widespread use of biologics for IBD to address an issue that had not been recognized previously. Google Scholar
  3. 3.
    Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15(9):1399–409.CrossRefPubMedGoogle Scholar
  4. 4.
    Desalermos AP, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2015;9(1):91–102.CrossRefPubMedGoogle Scholar
  5. 5.
    Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016; 12(9):540–546.Google Scholar
  6. 6.
    Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105(6):1231–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Melmed GY. Immunizations and IBD: whose responsibility is it? If I’m the prescribing doctor, shouldn’t it be mine? Inflamm Bowel Dis. 2012;18(1):41–2.CrossRefPubMedGoogle Scholar
  9. 9.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.CrossRefPubMedGoogle Scholar
  10. 10.
    Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):677–92.CrossRefPubMedGoogle Scholar
  11. 11.
    • Long MD, Gulati A, Wohl D, Herfarth H. Immunizations in pediatric and adult patients with inflammatory bowel disease: a practical case-based approach. Inflamm Bowel Dis. 2015;21(8):1993–2003. A practical clinically relevant article that can help clinicians at the bedside decide what vaccines are appropriate for their patients CrossRefPubMedGoogle Scholar
  12. 12.
    Stobaugh DJ, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol. 2013;6:43–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza Other Respir Viruses. 2013;7(Suppl 2):72–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Andrisani G, Frasca D, Romero M, Armuzzi A, Felice C, Marzo M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7(4):301–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67(5):713–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8(3):223–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):444–53.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Melmed GY. Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol. 2012;107(1):141–2.CrossRefPubMedGoogle Scholar
  19. 19.
    Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med 2016; 164(3):184–194.Google Scholar
  21. 21.
    de Bruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–47.CrossRefGoogle Scholar
  22. 22.
    Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60(4):456–62.CrossRefPubMedGoogle Scholar
  23. 23.
    Reich JS, Miller HL, Wasan SK, Noronha A, Ardagna E, Sullivan K, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11(6):396–401.Google Scholar
  24. 24.
    Cohen JI. A new vaccine to prevent herpes zoster. N Engl J Med. 2015;372(22):2149–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Marin AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11273–81.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    • Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017; 112(2):241–58. An up-to-date evidence-based guideline for all of the issues mentioned in this article. Google Scholar
  27. 27.
    Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35(20):2633–41.CrossRefPubMedGoogle Scholar
  28. 28.
    Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(8):797–813.CrossRefPubMedGoogle Scholar
  29. 29.
    Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4(2):152–156.Google Scholar
  30. 30.
    Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7):599–604.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93(9):1483–90.CrossRefPubMedGoogle Scholar
  32. 32.
    Shen B, Remzi FH, Oikonomou IK, Lu H, Lashner BA, Hammel JP, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009;104(3):639–46.CrossRefPubMedGoogle Scholar
  33. 33.
    Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62(2):105–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105–11.CrossRefPubMedGoogle Scholar
  36. 36.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.CrossRefPubMedGoogle Scholar
  37. 37.
    Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(8):1158–60.CrossRefPubMedGoogle Scholar
  39. 39.
    Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136(2):451–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Sinclair JA, Wasan SK, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin N Am. 2012;41(2):325–37.CrossRefGoogle Scholar
  41. 41.
    Committee on Practice B-G. Practice bulletin no. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):e111–30.CrossRefGoogle Scholar
  42. 42.
    Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(3):752–62.CrossRefPubMedGoogle Scholar
  43. 43.
    Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejon A, et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12(8):692–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Ananthakrishnan AN, Gainer VS, Cai T, Perez RG, Cheng SC, Savova G, et al. Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2013;108(4):594–601.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Smithson S, Pignone MP. Screening adults for depression in primary care. Med Clin North Am. 2017;101(4):807–21.CrossRefPubMedGoogle Scholar
  46. 46.
    Deter HC, Keller W, von Wietersheim J, Jantschek G, Duchmann R, Zeitz M, et al. Psychological treatment may reduce the need for healthcare in patients with Crohn’s disease. Inflamm Bowel Dis. 2007;13(6):745–52.CrossRefPubMedGoogle Scholar
  47. 47.
    Mahid SS, Minor KS, Stevens PL, Galandiuk S. The role of smoking in Crohn’s disease as defined by clinical variables. Dig Dis Sci. 2007;52(11):2897–903.CrossRefPubMedGoogle Scholar
  48. 48.
    Odes HS, Fich A, Reif S, Halak A, Lavy A, Keter D, et al. Effects of current cigarette smoking on clinical course of Crohn’s disease and ulcerative colitis. Dig Dis Sci. 2001;46(8):1717–21.CrossRefPubMedGoogle Scholar
  49. 49.
    Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107(9):1399–406.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Severs M, van Erp SJ, van der Valk ME, Mangen MJ, Fidder HH, van der Have M, et al. Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):455–61.CrossRefPubMedGoogle Scholar
  51. 51.
    Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41(1):1–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Nunes T, Etchevers MJ, Merino O, Gallego S, Garcia-Sanchez V, Marin-Jimenez I, et al. Does smoking influence Crohn’s disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis. 2013;19(1):23–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37(4):430–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Cosnes J. Smoking and diet: impact on disease course? Dig Dis. 2016;34(1–2):72–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Nunes T, Etchevers MJ, Domenech E, Garcia-Sanchez V, Ber Y, Penalva M, et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn’s disease in the biologic era. Aliment Pharmacol Ther. 2013;38(7):752–60.CrossRefPubMedGoogle Scholar
  56. 56.
    Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20(1):213–27.CrossRefPubMedGoogle Scholar
  57. 57.
    Moran GW, Lim AW, Bailey JL, Dubeau MF, Leung Y, Devlin SM, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(9):1002–24.CrossRefPubMedGoogle Scholar
  58. 58.
    Sifuentes H, Kane S. Monitoring for extra-intestinal cancers in IBD. Curr Gastroenterol Rep 2015; 17 (11):42.Google Scholar
  59. 59.
    Nissen LHC, Pierik M, Derikx L, de Jong E, Kievit W, van den Heuvel TRA, et al. Risk factors and clinical outcomes in patients with IBD with melanoma. Inflamm Bowel Dis. 2017;23:2018–26.CrossRefPubMedGoogle Scholar
  60. 60.
    Beaugerie L. Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented? Dig Dis. 2012;30(4):415–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Reasons Reported by Medicare Beneficiaries for Not Receiving Influenza and Pneumococcal Vaccinations -- United States, 1996. Accessed 2 Oct, 2017.
  62. 62.
    Pneumococcal Vaccine Recommendations | Vaccines and Immunizations | CDC. Accessed 2 Oct 2017.
  63. 63.
    ACIP Pneumococcal Vaccine Recommendations | CDC. Accessed 2 Oct 2017.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyUniversity of MissouriColumbiaUSA
  2. 2.Division of Gastroenterology and HepatologyMayo ClinicRochesterUSA

Personalised recommendations